Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $30
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst David Westenberg maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $54 to $30.
Piper Sandler analyst David Westenberg maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $54 to $30.